Beam Therapeutics (NASDAQ:BEAM) reported updated Phase 1/2 data for BEAM-302 showing increased alpha-1 antitrypsin levels and reductions in mutant Z-AAT among patients with alpha-1 antitrypsin deficiency.
Upstream Bio (NASDAQ:UPB) reported Phase 2 VALIANT trial results showing its verekitug treatment reduced annualized asthma exacerbation rates by 56% versus placebo in adults with severe asthma.
Novo Nordisk (NYSE:NVO) reported phase 3 STEP Young trial results showing once-weekly semaglutide plus lifestyle modification reduced BMI more than placebo in 165 children aged 6 to under 12 with obesity after 68 weeks.
Tarsus Pharmaceuticals (NASDAQ:TARS) completed its previously announced acquisition of Alkeus Pharmaceuticals, adding worldwide rights to investigational retinal disease therapy gildeuretinol (ALK-001).
Azenta (NASDAQ:AZTA) received full early repayment of a $35 million secured vendor loan related to the sale of B Medical Systems to Thelema S.à r.l.
Clearmind Medicine (NASDAQ:CMND) signed a definitive agreement to acquire a 51% stake in EV wireless charging company Charging Robotics for an aggregate purchase price of $2.5 million.
BioStem Technologies (NASDAQ:BSEM) announced that its VENDAJE® and VENDAJE AC® placental-derived wound care allografts have been added to existing contracts with Vizient and Premier, allowing hospitals to order the products immediately.
USA Rare Earth (NASDAQ:USAR) completed its combination with Serra Verde Group on September 3, 2026, creating an integrated rare earth and permanent magnet platform spanning Brazil, the United States, the United Kingdom, and France.
Immuron (NASDAQ:IMRN) announced an exclusive U.S. distribution agreement with Calmino group AB for PROIBS®, a digestive health product designed to support abdominal comfort and intestinal health.
Stoke Therapeutics (NASDAQ:STOK) and Biogen (NASDAQ:BIIB) reported long-term clinical data for investigational Dravet syndrome treatment zorevunersen from Phase 1/2a and open-label extension studies.
Ionis Pharmaceuticals (NASDAQ:IONS) announced that the U.S. Food and Drug Administration approved ZANVASTRO (zilganersen) for pediatric and adult patients with Alexander disease, making it the first disease-modifying treatment approved for the condition.
Milestone Pharmaceuticals (NASDAQ:MIST) received regulatory approval from China's National Medical Products Administration for its etripamil nasal spray, triggering a $2 million milestone payment.
